Literature DB >> 9618888

An evaluation of serum fructosamine as a marker of the duration of hypoproteinaemic conditions in dogs.

S I Thoresen1, W P Bredal.   

Abstract

Serum samples were collected from 153 normoglycaemic, hypoproteinaemic dogs of known case histories, and assayed for fructosamine, glucose, total protein and albumin concentrations. This study was conducted to evaluate the relationship between serum fructosamine and total serum proteins, or more specifically serum albumin. Serum fructosamine was positively correlated with both total serum protein (r = 0.47, p < 0.00001) and serum albumin (r = 0.77, p < 0.00001). Mean serum albumin concentrations were significantly different when the data were grouped as dogs with normal versus subnormal serum fructosamine concentrations. The data indicate the value of the serum fructosamine assay in estimating the duration of hypoalbuminaemia. Concurrent hypoalbuminaemia and normal serum fructosamine indicate hypoalbuminaemia of less than one week. Concurrent hypoalbuminaemia and hypofructosaminaemia indicate persistent hypoalbuminaemia of more than one week, and concurrent normal albumin and hypofructosaminaemia indicate recovery from a condition including hypoalbuminaemia or hypoglycaemia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618888     DOI: 10.1023/a:1006069104571

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  21 in total

1.  Clinical usefulness of fructosamine measurements in diagnosing and monitoring feline diabetes mellitus.

Authors:  S I Thoresen; W P Bredal
Journal:  J Small Anim Pract       Date:  1996-02       Impact factor: 1.522

2.  A comparative study of hexokinase from yeast and animal tissues.

Authors:  M W SLEIN; G T CORI; C F CORI
Journal:  J Biol Chem       Date:  1950-10       Impact factor: 5.157

3.  Serum fructosamine in canine diabetes mellitus. An initial study.

Authors:  A L Jensen
Journal:  Vet Res Commun       Date:  1992       Impact factor: 2.459

4.  Influence of variations in albumin or total-protein concentration on serum fructosamine concentration.

Authors:  M P Van Dieijen-Visser; C Seynaeve; P J Brombacher
Journal:  Clin Chem       Date:  1986-08       Impact factor: 8.327

5.  Specific glycation of albumin depends on its half-life.

Authors:  E D Schleicher; B Olgemöller; E Wiedenmann; K D Gerbitz
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

6.  Fructosamine Test-Plus, a modified fructosamine assay evaluated.

Authors:  J Baker; P Metcalf; R Scragg; R Johnson
Journal:  Clin Chem       Date:  1991-04       Impact factor: 8.327

7.  Relation of fructosamine to serum protein, albumin, and glucose concentrations in healthy and diabetic dogs.

Authors:  M Kawamoto; J J Kaneko; A A Heusner; E C Feldman; I Koizumi
Journal:  Am J Vet Res       Date:  1992-05       Impact factor: 1.156

8.  Various protein and albumin corrections of the serum fructosamine concentration in the diagnosis of canine diabetes mellitus.

Authors:  A L Jensen
Journal:  Vet Res Commun       Date:  1993       Impact factor: 2.459

9.  Simple colorimetry of glycated serum protein in a centrifugal analyzer.

Authors:  D Lloyd; J Marples
Journal:  Clin Chem       Date:  1984-10       Impact factor: 8.327

10.  Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites.

Authors:  N Iberg; R Flückiger
Journal:  J Biol Chem       Date:  1986-10-15       Impact factor: 5.157

View more
  3 in total

1.  Serum fructosamine concentrations in dogs with hypothyroidism.

Authors:  C E Reusch; B Gerber; F S Boretti
Journal:  Vet Res Commun       Date:  2002-10       Impact factor: 2.459

2.  Study of the effect of total serum protein and albumin concentrations on canine fructosamine concentration.

Authors:  A Loste; M C Marca
Journal:  Can J Vet Res       Date:  1999-04       Impact factor: 1.310

3.  Relationship between HbA1c, fructosamine and clinical assessment of glycemic control in dogs.

Authors:  Olga Norris; Thomas Schermerhorn
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.